ACADIA Pharmaceuticals Inc. ROIC

ROIC of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2020 was -401.62% (a -70.02% decrease from previous year)
  • Annual ROIC for 2019 was -1339.8% (a -51.84% decrease from previous year)
  • Annual ROIC for 2018 was -2782.02% (a -Infinity% decrease from previous year)
  • Twelve month ROIC ending March 30, 2021 was -255.98% (a -36.26% decrease compared to previous quarter)
  • Twelve month trailing ROIC decreased by -77.75% year-over-year
Trailing ROIC for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
-255.98% -401.62% -289.12% -1150.58%
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of ACADIA Pharmaceuticals Inc.

Most recent ROICof ACAD including historical data for past 10 years.

Interactive Chart of ROIC of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -401.62%
2019 -1339.8%
2018 -2782.02%
2017 0.0%
2016 0.0%
2015 0.0%
2014 0.0%
2013 0.0%
2012 0.0%
2011 0.0%
2010 0.0%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.